Research Article
Print
Research Article
Production of rare cycloartane saponins from Astragalus thracicus (Griseb) compared to Astragalus membranaceus (Fisch.) Bunge – native and biotechnological sources
expand article infoPreslav Enchev‡, Yancho Zarev‡, Hans Michler§, Iliana Ionkova‡
‡ Medical University of Sofia, Sofia, Bulgaria
§ Centre of Pharma Research, Institute of Pharmaceutical Biology, Munich, Germany

Corresponding author: Yancho Zarev ( zarev.yancho@gmail.com )

Academic editor: Plamen Peikov
© 2023 Preslav Enchev, Yancho Zarev, Hans Michler, Iliana Ionkova.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation: Enchev P, Zarev Y, Michler H, Ionkova I (2023) Production of rare cycloartane saponins from Astragalus thracicus (Griseb) compared to Astragalus membranaceus (Fisch.) Bunge – native and biotechnological sources. Pharmacia 70(1): 73-77. https://doi.org/10.3897/pharmacia.70.e97782
Open Access

Abstract

The aim of this study is a comparative metabolomic analysis between the endangered species Astragalus membranaceus and endemic species Astragalus thracicus concerning cycloartane saponins. In addition, in vitro shoots, callus, and suspension cultures of A. thracicus were successfully established to conserve the biodiversity of those endemic species and to increase the amount of produced saponins. The comparison was made according to the quantity of cycloartane saponins astragaloside I (1), astragaloside II (2), and astragaloside IV (4) to the reference standards for the same compounds by UHPLC-HRESI-MS analysis. The in vitro root cultures of A. thracicus reached two folds higher amounts of saponins (1.50 mg/g DW (1), 1.01 mg/g DW (2), and 0.91 mg/g DW (3)) than the native root of A. thracicus (1.14 mg/g DW (1) 0.47 mg/g DW (2), 0.40 mg/g DW (3)), and up to six times higher when compared with roots A. membranaceus (0.23 mg/g DW (1), 0.18 mg/g DW (2) and 0.05 mg/g DW (3)).

Keywords

LC/MS analysis, cycloartane saponins, Astragalus thracicus, Astragalus membranaceus, in vitro cultures

Introduction

The proven immunomodulatory, antiviral, and antitumor effects of representatives of the Astragalus genus are mainly due to the triterpene saponins of the cycloartane type contained in them. Due to the complexity of their structure, they are still most efficiently obtained from native plants. Variations in the quantity and quality of the plant material, a long period of development before starting saponin production (Astragalus roots), and the excessive collection of endangered species for pharmaceutical purposes (A. membranaceus) are just some of the problems associated with obtaining these natural products. Therefore, the discovery of new plant species (A. thracicus) that contain them is essential for the pharmaceutical industry. Thus, comparative metabolomic analysis between endangered Asia species A. membranaceus and Bulgaria endemic species A. thracicus could provide important information about possible alternative sources. In addition, biotechnological methods could serve as an opportunity to protect those endemic species and to increase the amount of produced saponins.

Astragalus L. Fabaceae (Leguminosae) is the largest genus of herbaceous plants in the pea and bean family it includes approximately 3000 species, distributed across Asia, Africa, Europe, South, and North America, although the center of origin and biodiversity of plants of the genus Astragalus is Eurasia, and in particular, the mountainous parts of Southwest Asia (Podlech 2008).

The most used species of the genus is A. membranaceus Bunge var. mongholicus (Bunge), (syn. A. mongholicus var. mongholicus), the drug used to be the dried whole or thinly sliced roots. The plant substance, due to its wide use, has been included in the editions of the European Pharmacopoeia after 2012 (Ph. Eur. monograph, as well as in the Chinese Materia medica.

Phytochemical studies on Astragalus species have been conducted due to their effects as immunostimulants or as anticancer agents (Ionkova et al. 2014; Krasteva et al. 2016). In particular, the chemical composition of the dried roots of Astragalus spp. protects the heart, brain, kidneys, intestines, liver, and lungs from various diseases associated with oxidative stress (Hong et al. 1992; Shahzad et al. 2016). Various isolated components of Astragalus spp. show significant antiproliferative activity. The highest activity against T-cell leukemia (SKW-3) cells was registered for rhamnocitrin 4’-D-galactopyranoside isolated from A. hamosus (Krasteva et al. 2008).

Biotechnological techniques and approaches are an extremely attractive alternative to over-exploited wild species. Some of the advantages of the in vitro techniques are the propagation of the plants in aseptic controlled conditions and their large-scale production in a year-round system without seasonal constraints (Isah et al. 2018). The plant cell techniques provide some high-efficiency methods for isolation and extraction of the secondary metabolites within a short time compared to the wild plant populations and the simplicity of the methods from in vitro-produced tissues makes it suitable for commercial application (Kolewe et al. 2008). Apart from these advantages, some metabolites can be produced by in vitro cultures but are generally not found in intact plants (Pavlov et al. 2005).

Materials and methods

Plant material

The in vitro cultures of A. thracicus were successfully established and maintained in our lab. The native A. thracicus roots were carefully collected from their natural environment, while native A. membranaceus roots were delivered by HerbaSinica Hilsdorf GmbH (Ch.-B. 160601H004).

General experimental procedures

All solvents were at least of analytical grade, whereas solvents used for semi-preparative HPLC analysis, i.e., EtOAc and MeOH were HPLC grade and were purchased from Fischer Scientific (Loughborough, UK). The following reference substances of cycloartane saponins were used: Astragaloside I (≥ 95.0%) delivered by Cayman chemical company; Astragaloside II (≥ 99.8%) obtained from Sigma-Aldrich and Astragaloside IV (≥ 98.0%) purchased from Tokyo chemical industry Co., LTD.

All analyses were performed with a Dionex Ultimate 3000 RSLC UHPLC-HRESI-MS system from Thermo Scientific (Germering, Germany) consisting of 6-channel degasser SRD-3600, high-pressure gradient pump HPG-3400RS, autosampler WPS-3000TRS, and column compartment TCC-3000RS coupled to Thermo Scientific Q Exactive Plus (Bremen, Germany) mass spectrometer. The full scan MS was set at 16 minutes duration with runtime from 1.06 to 13.96 minutes, resolution 70000; AGC target 3e6, max IT 100 ms, scan range 150 to 2000 m/z. The MS scan was set at 17500 resolution and AGC target 1e5, maximum IT, scan range 200 to 2000 m/z, isolation window 2.0 m/z, and (N) CE 20, 40, 60. The ionization source (HRESI) was set at: +3.5 to -2.5 kV spray voltage and 320 °C capillary and probe temperature, 38 arbitrary units (a.u., as set by the Extractive Tune software) of sheath gas and 12 a.u. of auxiliary gas (both Nitrogen); S-Lens RF level 50.0. UHPLC separations were performed on a Kromasil C18 column (1.9 μm, 2.1 × 50 mm, Akzo Nobel, Sweden) at 40 °C. The mobile phase was H2O + 0.1% HCOOH (A) and MeCN + 0.1% HCOOH (B) with a flow rate of 0.3 mL/min. Elution was performed as follows: 25% B for 0.5’, gradient to 35% B for 1.5’, gradient to 40% B for 5’, increase to 45% in 4’, increase to 95% in 3’, and isocratic 95% for another 2’.

Analysis and quantification of cycloartane saponins

Astragaloside I (1), Astragaloside II (2), and Astragaloside IV (3) were used as external standards for the quantitative analysis of saponins. Each of the standards was dissolved in 50% MeOH and then subsequently diluted to reach 5 concentration levels used to build the calibration curves for quantitative assay covering the concentration range of 1.35–21.60 µg/mL for Astragaloside I; 1.20–19.00 µg/mL for Astragaloside II and 2.00–27 µg/mL for Astragaloside IV, respectively. All solutions were stored in the refrigerator at 4 °C.

Extraction and purification of crude extracts

The dried plant material from in vitro cultures of A. thracicus, native A. thracicus roots, and A. membranaceus roots were exhaustively extracted with 80% MeOH. The extracts were filtered and concentrated under reduced pressure and after that fractionated by solid phase extraction (SPE) using C18 cartridges (500 mg) to obtain H2O, EtOAc, and MeOH fractions. Further separation of the fractions was achieved by blotting the samples onto Diaion HP 20, and subsequently eluted with 100 mL 40% and 90% MeOH for each of the EtOAc fractions and 30% and 90% MeOH respectively for each of the MeOH fractions, which resulted in 4 fractions for each initial extract (Scheme 1). Each of the fractions was subjected to UHPLC-HRESI-MS analysis.

Scheme 1. 

Extraction and purification of crude extracts from in vitro cultures of A. thracicus, native A. thracicus roots, and native A. membranaceus roots.

Results and discussion

In vitro cultivation

Shoot culture from A. thracicus was derived from MS medium, while the roots were obtained by cultivation in the dark regimen of cultivation using modified MS medium supplemented with 2 mg/L NAA (Ms-Li). The suspension cultures were initiated when cultivated on MS medium supplemented with 2 mg/L kinetin, 0.2 mg/L IAA, 0.1 mg/L 2,4-D, and 1 g/L casein (G48) and cultivated in a dark and light regimen of cultivation (Ionkova et al. 2010).

Identification of cycloartane saponins

Within UHPLC-HRESI-MS analysis astragaloside I, II, and IV were determined at negative ion mode as adducts with HCOOH. For astragaloside I (1) HRESIM spectrum showed a protonated molecular ion at m/z 913.4805 [M+FA-H]- corresponding to molecular formula C46H73O18 (calc. m/z 913.4791) and tR 9.12’ (Suppl. material 1: fig. S1). Astragaloside II (2) was observed as a protonated molecular ion at m/z 871.4699 [M+FA-H]- corresponding to molecular formula C44H71O17 (calc. m/z 871.4686) and tR 5.61’ (Suppl. material 1: fig. S2), while astragaloside IV (3) produce a protonated molecular ion at m/z 829.45941 [M+FA-H]- corresponding to molecular formula C42H69O16 (calc. m/z 829.4580) and tR 4.31’ (Fig. 1). The compounds in samples were identified according to the described above retention times, m/z ratios and spectrum fragmentations. The three important cycloartane metabolites (1–3) were found in all analyzed samples from A. thracicus and A. membranaceus.

Figure 1. 

A chromatogram of the standard mixture of saponins.

Calibration model

A visual evaluation of the linear regression line plot showed that the method was linear for all of the standards (Fig. 2). The determination coefficient for compound 1 was r2 = 0.9858, for compound 2 r2 = 0.9932 and compound 3 r2 = 0.9960, respectively. After the linearity was investigated the regression analysis was performed. The determination coefficients and regression equations are presented in Table 1.

Table 1.
Download as
CSV
XLSX

Determination coefficient and regression equations of compound 1–3.

Astragaloside I (1) Astragaloside II (2) Astragaloside IV (3)
Determination coefficient 0.9858 0.9932 0.9960
Linear range (µg/mL) 1.35–21.60 1.20–19.20 1.66–26.60
Regression equations Y = 7E+06X–1E+07 Y = 6E+06X–7E+06 Y = 1E+07X–1E+07
Number of standards 5 5 5
Rt (min) 9.12 5.61 4.31
Figure 2. 

Calibration curve for Astragaloside I (1), Astragaloside II (2), and Astragaloside IV (3).

Quantification of cycloartane saponins

The amount of the individual saponins was calculated due to the calibration equation formula for Astragaloside I y = 7E+06x–1E+07; Astragaloside II y = 6E+06x–7E+06 and Astragaloside IV y = 1E+07x–1E+07 within each of the derived fractions from in vitro cultures of A. thracicus, native roots of A. thracicus and native roots of A. membranaceus. In general, the highest amount of compounds 1–3 was found in EtOAc 90% fractions, except compound 3, which eluted in large amounts also in MeOH 90% (Suppl. material 1: figs S4–S6). This unexpected chromatographic behavior may be related to the absence of an acetylene residue in the sugar moiety of the molecule, which probably makes it more polar. This can also be confirmed by the retention times from the LC-HRESI-MS analysis of a mixture including the three saponins (Fig. 1).

Cycloartane saponins were proved in the highest amount (1.50 mg/g DW (1), 1.01 mg/g DW (2), and 0.91 mg/g DW (3)) in in vitro root cultures from A. thracicus. Even for astragaloside II and IV, the amount was two folds higher than the amount in native roots (0.47 mg/g DW (2), 0.40 mg/g DW (3)). In vitro shoot cultures of A. thracicus also produce a higher amount of astragaloside II and IV (0.80 mg/g DW (2), 0.48 mg/g DW (3)) than the native source provides. Аn expected low amount of cycloartane saponins was observed in suspension culture cultivated on G48 medium such as those grown in the dark could produce a higher amount of astragaloside I (0.34 mg/g DW), while astragaloside II and IV are observed in higher amounts (0.25 mg/g DW and 0.35 mg/g DW) when suspension cultures are cultivated at light regimen. In all, in vitro cultures of A. thracicus the observed metabolites were in higher abundance than in native roots of A. membranaceus (0.23 mg/g DW (1), 0.18 mg/g DW (2) and 0.05 mg/g DW (3)) (Fig. 3).

Figure 3. 

Cycloartane saponins mg/g DW in native roots of A. thracicus and A. membranaceus, compared to in vitro cultures of A. thracicus.

Conclusion

The comparative LC-HRESI-MS analysis showed for the first time that the endemic species A. thracicus biosynthesized identical rare cycloartane saponins as A. membranaceus. In the present study, a new biotechnological platform was also created that provides a higher production of cycloartane saponins–astragaloside I, II, and IV compared to the wild species. The in vitro root cultures of A. thracicus reached two folds higher amounts of saponins than native root of A. thracicus, and up to six times higher when compared with A. membranaceus. In addition, our results provide a fast LC-HRESI-MS protocol for the identification of cycloartane saponins.

Acknowledgements

This study was financially supported by the Council of Medicinal Science at the Medical University of Sofia, contract № D-155/14.06.2022.

References

  • Ionkova I, Antonova I, Momekov G, Fuss E (2010) Production of podophyllotoxin in Linum linearifolium in vitro cultures. Pharmacognosy Magazine 6(23): 180–185. https://doi.org/10.4103/0973-1296.66932
  • Ionkova I, Shkondrov A, Krasteva I, Ionkov T (2014) Recent progress in phytochemistry, pharmacology and biotechnology of Astragalus saponins. Phytochemistry Reviews 13(2): 343–374. https://doi.org/10.1007/s11101-014-9347-3
  • Ionkova I, Shkondrov A, Zarev Y, Kozuharova E, Krasteva I (2022) Anticancer secondary metabolites: from ethnopharmacology and identification in native complexes to biotechnological studies in species of genus Astragalus L. and Gloriosa L. Current Issues in Molecular Biology 44(9): 3884–3904. https://doi.org/10.3390/cimb44090267
  • Krasteva I, Shkondrov A, Ionkova I, Zdraveva P (2016) Advances in phytochemistry, pharmacology and biotechnology of Bulgarian Astragalus species. Phytochemistry Reviews 15(4): 567–590. https://doi.org/10.1007/s11101-016-9462-4
  • Shahzad M, Shabbir A, Wojcikowski K, Wohlmuth H, Gobe GC (2016) The Antioxidant effects of radix Astragali (Astragalus membranaceus and related species) in protecting tissues from injury and disease. Current Drug Targets 17(12): 1331–1340. https://doi.org/10.2174/1389450116666150907104742
  • Krasteva I, Momekov G, Zdraveva P, Konstantinov S, Nikolov S (2008) Antiproliferative effects of a flavonoid and saponins from Astragalus hamosus against human tumor cell lines. Pharmacognosy Magazine 4(16): 269–272.
  • Isah T, Umar S, Mujib A, Sharma MP, Rajasekharan PE, Zafar N, Frukh A (2018) Secondary metabolism of pharmaceuticals in the plant in vitro cultures: Strategies, approaches, and limitations to achieving higher yield. Plant Cell Tissue and Organ Culture 132(13): 239–265. https://doi.org/10.1007/s11240-017-1332-2
  • Kolewe ME, Gaurav V, Roberts SC (2008) Pharmaceutical active natural product synthesis and supply via plant cell culture technology. Molecular Pharmaceutics 5(2): 243–256. https://doi.org/10.1021/mp7001494

Supplementary material

Supplementary material 1 

HR-ESI-MS of Astragaloside I, Astragaloside II and Astragaloside IV

Preslav Enchev, Yancho Zarev, Hans Michler, Iliana Ionkova

Data type: .zip file

Explanation note: The amount of Astragaloside I (1), Astragaloside II (2) and Astragaloside IV (3) determined in each of the fraction obtained from in vitro cultures of A. thracicus, native roots of A. thracicus and native roots of A. membranaceus.

This dataset is made available under the Open Database License (http://opendatacommons.org/licenses/odbl/1.0). The Open Database License (ODbL) is a license agreement intended to allow users to freely share, modify, and use this Dataset while maintaining this same freedom for others, provided that the original source and author(s) are credited.
Download file (468.93 kb)
login to comment